3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
44
Squamous Cell Carcinoma of Head and Neck
19
Breast Neoplasms
18
Lung Neoplasms
17
Colorectal Neoplasms
15
Neoplasms
12
Neoplasm Metastasis
12
Head and Neck Neoplasms
12
Ovarian Neoplasms
11
Small Cell Lung Carcinoma
9
Recurrence
9
Sarcoma
8
Pancreatic Neoplasms
8
Prostatic Neoplasms
7
Advanced Solid Tumors
7
Urinary Bladder Neoplasms
6
Triple Negative Breast Neoplasms
6
Melanoma
6
Lymphoma, Large B-Cell, Diffuse
6
Diabetes Mellitus, Insulin-Dependent, 12
6
Uterine Cervical Neoplasms
5
Carcinoma, Renal Cell
5
Carcinoma, Hepatocellular
5
Biliary Tract Neoplasms
5
Mesothelioma, Malignant
4
Lymphoma, Follicular
4
Lymphoma
4
Fallopian Tube Neoplasms
4
Esophageal Neoplasms
4
Cholangiocarcinoma
4
Interventions
Cyclophosphamide
125
Peripheral Blood Stem Cell Transplantation
84
fludarabine phosphate
81
Etoposide
73
Filgrastim
64
Mycophenolic Acid
63
Tacrolimus
57
Whole-Body Irradiation
55
Busulfan
52
Doxorubicin
50
Radiotherapy
48
Melphalan
48
Cyclosporine
47
Brentuximab Vedotin
45
Rituximab
39
Vinblastine
37
fludarabine
36
Granulocyte Colony-Stimulating Factor
36
Antilymphocyte Serum
35
Prednisone
33
Methotrexate
32
Vincristine
31
Gemcitabine
30
Dacarbazine
29
Bleomycin
29
Cytarabine
26
Carmustine
22
Bendamustine Hydrochloride
21
Sirolimus
18
Ifosfamide
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Hodgkin Disease
×
durvalumab
×
Clear all
NCT02733042
2023-11-18
FUSION NHL 001
Celgene
Phase 1/2
Completed
106 enrolled
48 charts